+

WO2000043419A3 - Exocytosis pathway proteins and methods of use - Google Patents

Exocytosis pathway proteins and methods of use Download PDF

Info

Publication number
WO2000043419A3
WO2000043419A3 PCT/US2000/001431 US0001431W WO0043419A3 WO 2000043419 A3 WO2000043419 A3 WO 2000043419A3 US 0001431 W US0001431 W US 0001431W WO 0043419 A3 WO0043419 A3 WO 0043419A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
methods
nucleic acid
exocytosis
Prior art date
Application number
PCT/US2000/001431
Other languages
French (fr)
Other versions
WO2000043419A2 (en
Inventor
Ying Luo
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Priority to CA002359145A priority Critical patent/CA2359145A1/en
Priority to EP00902456A priority patent/EP1161442A2/en
Priority to JP2000594835A priority patent/JP2003521230A/en
Priority to AU24166/00A priority patent/AU2416600A/en
Publication of WO2000043419A2 publication Critical patent/WO2000043419A2/en
Publication of WO2000043419A3 publication Critical patent/WO2000043419A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention is directed to novel polypeptides such as the Exo protein and related molecules which have an effect on or are related to exocytosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are method for identifying novel compositions which mediated Exo bioactivity, and the use of such compositions in diagnosis and treatment of disease.
PCT/US2000/001431 1999-01-20 2000-01-20 Exocytosis pathway proteins and methods of use WO2000043419A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002359145A CA2359145A1 (en) 1999-01-20 2000-01-20 Exocytosis pathway proteins and methods of use
EP00902456A EP1161442A2 (en) 1999-01-20 2000-01-20 Exocytosis pathway proteins and methods of use
JP2000594835A JP2003521230A (en) 1999-01-20 2000-01-20 Exocytosis pathway proteins and methods of use
AU24166/00A AU2416600A (en) 1999-01-20 2000-01-20 Exocytosis pathway proteins and methods of use

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US11653499P 1999-01-20 1999-01-20
US60/116,534 1999-01-20
US11730999P 1999-01-26 1999-01-26
US11730899P 1999-01-26 1999-01-26
US11727499P 1999-01-26 1999-01-26
US11731299P 1999-01-26 1999-01-26
US60/117,308 1999-01-26
US60/117,309 1999-01-26
US60/117,274 1999-01-26
US60/117,312 1999-01-26
US11817799P 1999-02-01 1999-02-01
US11817899P 1999-02-01 1999-02-01
US11817999P 1999-02-01 1999-02-01
US60/118,178 1999-02-01
US60/118,179 1999-02-01
US60/118,177 1999-02-01
US11928699P 1999-02-09 1999-02-09
US60/119,286 1999-02-09
US11975999P 1999-02-11 1999-02-11
US11999899P 1999-02-11 1999-02-11
US60/119,998 1999-02-11
US60/119,759 1999-02-11

Publications (2)

Publication Number Publication Date
WO2000043419A2 WO2000043419A2 (en) 2000-07-27
WO2000043419A3 true WO2000043419A3 (en) 2001-02-15

Family

ID=27582648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001431 WO2000043419A2 (en) 1999-01-20 2000-01-20 Exocytosis pathway proteins and methods of use

Country Status (5)

Country Link
EP (1) EP1161442A2 (en)
JP (1) JP2003521230A (en)
AU (1) AU2416600A (en)
CA (1) CA2359145A1 (en)
WO (1) WO2000043419A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952550A0 (en) * 2002-11-08 2002-11-21 The University Of Queensland Modulating TNFalpha Secretion
WO2011138391A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
ES2659406T3 (en) 2010-05-06 2018-03-15 Novartis Ag Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6)
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
CN116790760B (en) * 2023-08-17 2023-12-12 北京大学人民医院 Colon cancer-specific circular RNA markers and their detection primers and applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055152A1 (en) * 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
WO1999042586A2 (en) * 1998-02-23 1999-08-26 Rigel Pharmaceuticals, Inc. Exo1 and exo2, exocytotic proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055152A1 (en) * 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
WO1999042586A2 (en) * 1998-02-23 1999-08-26 Rigel Pharmaceuticals, Inc. Exo1 and exo2, exocytotic proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARAKI, S. ET AL.: "Inhibition of the Binding of SNAP-23 to Syntaxin 4 by Munc18c", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 234, no. 1, 8 May 1997 (1997-05-08), pages 257 - 262, XP002109868 *
EMBL Database, Heidelberg, FRG Emest_Rod11 accession number AA060253 24 September 1996 MARRA, M. ET AL.: "mj72a10.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone IMAGE:481626 5', mRNA sequence" *
OYAMA, Y. ET AL.: "Two Distinct Anti-allergic Drugs, Amlexanox and Cromolyn, Bind to the Same Kinds of Calcium Binding Proteins, except Calmodulin, in Bovine Lung Extract", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 240, no. 2, 17 November 1997 (1997-11-17), pages 341 - 347, XP002109865 *
TANG, B.L. ET AL.: "Syntaxin 12, a Member of the Syntaxin Family Localized to the Endosome", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 12, 20 March 1998 (1998-03-20), pages 6944 - 6950, XP002144550 *

Also Published As

Publication number Publication date
CA2359145A1 (en) 2000-07-27
EP1161442A2 (en) 2001-12-12
AU2416600A (en) 2000-08-07
JP2003521230A (en) 2003-07-15
WO2000043419A2 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
WO1999055868A3 (en) Fizz proteins
EP1690872A3 (en) Composition and methods for the diagnosis of tumours
CY1112334T1 (en) Homologous IL-17 Polypeptides and their therapeutic uses
WO1999061469A3 (en) Prostate growth-associated membrane proteins
WO2001042437A3 (en) Histone deacetylase-8 proteins, nucleic acids, and methods of use
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2001064913A3 (en) Cell cycle proteins associated with rad9, compositions and methods of use
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
WO2001030987A3 (en) Tankyrase h, compositions involved in the cell cycle and methods of use
WO2001021654A3 (en) Syk kinase-associated cell cycle proteins, compositions and methods of use
WO1999042586A3 (en) Exo1 and exo2, exocytotic proteins
WO2001036476A3 (en) Ing2, an iaps associated cell cycle protein, compositions and methods of use
EP1241179A3 (en) Human cornichon-like protein and nucleic acids encoding it
WO2001021784A3 (en) Pcna-associated cell cycle proteins, compositions and methods of use
WO2001029197A3 (en) Novel germinal center kinase cell cycle proteins, compositions and methods of use
WO2001036474A3 (en) Srik a novel cell cycle protein associated with rip3
WO2000007545A8 (en) Apoptosis proteins
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP1251139A3 (en) Human mindin-like protein and nucleic acids encoding it
EP2050762A3 (en) Human cornichon-like protein and nucleic acids encoding it
EP1666497A3 (en) Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
WO2001029072A3 (en) P15paf cell cycle proteins associated with pcna, compositions and methods of use
EP1247817A3 (en) Human CD23-like protein and nucleic acids encoding it
EP1241252A3 (en) Human enteropeptidase-like protein and nucleic acids encoding it
EP1241250A3 (en) Human dehydrogenase-like protein and nucleic acid encoding it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 594835

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 24166/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000902456

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2359145

Country of ref document: CA

Ref country code: CA

Ref document number: 2359145

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000902456

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000902456

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载